Jubilant Pharmova to invest $92m in sterile injections plant in US
Jubilant Pharmova said that its fully-owned subsidiary – Jubilant Pharma will invest $92 million to expand its manufacturing capacity of sterile injections at its Spokane site in Washington state.
The investment will enable Jubilant Pharma to install a high speed injectable fill line with isolator technology that can produce 400 vials a minute, thereby boosting the Spokane plant’s capacity by 50%.
The expansion will also include a couple of 300sft Lyophilizers.
According to Jubilant Pharmova, the expansion will span more than 50,000sft at the Spokane facility and will begin commercial operations by the end of 2024.
Pramod Yadav – CEO Jubilant Pharma said: “We are pleased to announce the planned expansion of the sterile injectable manufacturing capacity at this critical juncture. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic and are prepared for a potential future pandemic response.
“This expansion will also help us meet high demand from our global Specialty Pharmaceutical customers, with whom the company has established strong relationships.”